A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

The report forecasted that the Alzheimer's disease market in these countries to grow from $2.4 billion in 2023 to $19.3 ...

Anavex Life Sciences shares were up 7% to $11.25 after the company said it saw positive trial results for its oral blarcamesine for the treatment of early Alzheimer's disease. The clinical-stage ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

19, 2024 — Researchers have discovered a surprising link between a chronic gut infection caused by a common virus and the development of Alzheimer's disease ... Alzheimer's Treatment One Step ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

Dementia, a progressive disorder that impacts memory and independence, affects millions globally. While many are aware of ...

Some research shows it may have benefits for people with Alzheimer’s disease, but current evidence ... the 22 studies they examined, melatonin therapy for more than 12 weeks was associated ...

Spear Bio Inc., a biotechnology company pioneering next-generation ultra-sensitive immunoassays, today announced that its pTau 217 blood test has been granted Breakthrough Device Designation by the U.

Researchers at the University of Kentucky (UK) are part of a groundbreaking clinical trial exploring the use of medical ...